You just read:

Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity

News provided by

Protagonist Therapeutics, Inc.

May 24, 2017, 08:00 ET